Last reviewed · How we verify
standard prednisolone treatment
Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders in children, Nephrotic syndrome, Asthma exacerbations.
At a glance
| Generic name | standard prednisolone treatment |
|---|---|
| Sponsor | Institute of Child Health |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / Pediatrics |
| Phase | FDA-approved |
Mechanism of action
Prednisolone enters cells and binds to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and proliferation. The drug is commonly used in pediatric settings to treat inflammatory and autoimmune conditions.
Approved indications
- Inflammatory and autoimmune disorders in children
- Nephrotic syndrome
- Asthma exacerbations
- Allergic reactions
- Autoimmune hemolytic anemia
- Idiopathic thrombocytopenic purpura
Common side effects
- Increased appetite and weight gain
- Insomnia and mood changes
- Immunosuppression and increased infection risk
- Hyperglycemia
- Osteoporosis (with chronic use)
- Cushingoid features
- Gastrointestinal upset
Key clinical trials
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- OMT for Adhesive Capsulitis (PHASE4)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- MAGIC Ruxolitinib for aGVHD (PHASE2)
- Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard prednisolone treatment CI brief — competitive landscape report
- standard prednisolone treatment updates RSS · CI watch RSS
- Institute of Child Health portfolio CI